Skip to main content

Table 3 Mean change in lipid content of lipoprotein fractions with pradigastat

From: Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

 

Treatment period 1

Treatment period 2

Treatment period 3

Pradigastat 20 mg (n = 6)

Pradigastat 40 mg (n = 6)

Pradigastat 10 mg (n = 4)

 

Baseline

EOT

% Change

Baseline

EOT

% Change

Baseline

EOT

% Change

CM-TG

22.11. (7.51)

8.95. (1.86)

−59.5%

51.97. (49.78)

12.64. (7.12)

−75.7%

52.90. (10.11)

30.93. (13.48)

−41.5%

CM-C

5.38. (2.20)

3.32. (0.89)

−38.3%

9.50. (6.28)

4.38. (3.23)

−53.9%

8.48. (2.91)

6.45. (3.46)

−23.9%

LDL-TG

0.65. (0.22)

0.55. (0.21)

−15.4%

1.33. (2.19)

0.36. (0.17)

−72.9%

0.65 (0.17)

0.50. (0.29)

−23.1%

LDL-C

0.99. (0.34)

1.10. (0.25)

11.1%

1.01. (0.40)

1.02. (0.26)

1.0%

0.93. (0.39)

0.79 (0.19)

−15.1%

HDL-TG

0.25. (0.1)

0.27. (0.1)

8.0%

0.25. (0.10)

0.22. (0.04)

−12.0%

0.20. (0.08)

0.25. (0.06)

25.0%

HDL-C

0.34. (0.12)

0.55. (0.09)

61.7%

0.14. (0.13)

0.46. (0.11)

228.6%

0.17. (0.21)

0.25. (0.14)

47.1%

VLDL-TG

2.75. (0.24)

2.40. (0.45)

−12.7%

2.52. (1.45)

3.06. (0.75)

21.4%

3.55. (1.53)

3.53. (1.62)

−0.6%

VLDL-C

1.10. (0.56)

1.08. (0.28)

−1.8%

0.51. (0.59)

1.40. (0.55)

63.6%

0.23. (0.25)

0.94. (0.45)

308.7%

  1. Data presented in mmol/L as arithmetic mean (SD) unless otherwise specified.
  2. C = cholesterol; CM = chylomicrons; EOT = end of treatment; HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglycerides; VLDL = very-low-density lipoprotein.
  3. Arithmetic means are presented since geometric means could not be calculated for all parameters due to zero values.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X